卖什么
Robotic production capacity for the pharma manufacturing industry
商业模式拆解
买家：谁掌握预算？
未核实VP manufacturing / CMC at advanced-therapy developers and CDMOs.
触发点：什么让他们现在购买？
Demand for advanced therapies outpaces manual cleanroom manufacturing; cost per dose, contamination risk and traceability.
工作流：什么输入变成什么输出？
Customer's existing GMP instruments are placed in a robotic cluster (4 UR arms, up to 24 instrument modules); scientists build the process in a no-code Process Creator App and robots execute it in a closed cleanroom.
经济账：省了什么，怎么收费？
Site claims 74% cost reduction per dose, 90% of cleanroom steps automated, 100x throughput per sq ft, 2,000-10,000+ doses/year per cluster; sold as robotic systems (price not shown).
渠道：怎么接触到客户？
Direct enterprise sales and collaborations ('Request an In-Person Visit').
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2016 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.